Apr 29, 2025 - Economy
GLP-1 roller coaster
Add Axios as your preferred source to
see more of our stories on Google.
Hims & Hers shares soared today after Novo Nordisk said it would sell weight-loss drug Wegovy at a discount on the telehealth platform.
- Why it matters: Hims is under pressure to offer GLP-1 drugs to its customers now that shortages are over and pharmacies are largely restricted from offering compounded versions of the medicines.
Driving the news: Novo will sell Wegovy on Hims, LifeMD and Ro via its direct-to-consumer platform NovoCare.
- The price will start at $499, a 63% discount in the U.S. before subscription fees, Bloomberg reported.
State of play: Novo rival Eli Lilly already has deals with other telehealth platforms like Ro to distribute its obesity drug Zepbound, starting at $349 for a month's supply, according to Bloomberg.
- Hims currently sells Zepbound at the full price.
By the numbers: Hims stock closed up 23% today, but is still off nearly 50% from its high in February, before the FDA declared that Ozempic and Wegovy were no longer in short supply.
